| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
(S)-Minzasolmin targets α-synuclein as an inhibitor of oligomerization. As the S-enantiomer of Minzasolmin, it is an isomer of the α-synuclein oligomerization inhibitor. α-Synuclein is a protein that misfolds and oligomerizes in Parkinson's disease and other synucleinopathies. The compound is used to study the stereochemical requirements for α-synuclein oligomerization inhibition. By comparing the activity of the S-enantiomer with the R-enantiomer (Minzasolmin), researchers can determine the importance of stereochemistry for target engagement.
|
|---|---|
| ln Vitro |
In vitro studies of (S)-Minzasolmin demonstrate that it is an isomer of Minzasolmin, an inhibitor of α-synuclein oligomerization. The compound is used as a research tool to study the stereochemical requirements for α-synuclein inhibition. By comparing the activity of the S-enantiomer with the R-enantiomer (Minzasolmin), researchers can determine the importance of stereochemistry for target engagement and potency. The compound has been characterized for its ability to inhibit α-synuclein oligomerization in cell-free and cell-based assays. Detailed in vitro characterization data are available in the primary literature.
|
| ln Vivo |
In vivo studies of (S)-Minzasolmin are limited in publicly available literature, as the compound is primarily used as a research tool to study stereochemical requirements. As the S-enantiomer of Minzasolmin, it may be used in comparative studies to assess the importance of stereochemistry for in vivo activity. Minzasolmin (the R-enantiomer) is orally bioavailable and brain-penetrant. The S-enantiomer may have different pharmacokinetic and pharmacodynamic properties. Further research is needed to establish its in vivo activity profile.
|
| Enzyme Assay |
For α-synuclein oligomerization inhibition assays, recombinant α-synuclein protein is incubated with varying concentrations of (S)-Minzasolmin under aggregation-promoting conditions. Oligomerization is monitored using specific antibodies or by size-exclusion chromatography. The compound's ability to inhibit oligomer formation is assessed and compared to the R-enantiomer (Minzasolmin). IC50 values are calculated from dose-response curves. For cell-based assays, neuronal cells expressing α-synuclein are treated with compound and oligomer levels are measured by immunofluorescence or Western blot. Assays are performed in replicate with vehicle controls.
|
| Cell Assay |
For in vitro cellular assays, neuronal cell lines (e.g., SH-SY5Y cells) or primary neurons expressing α-synuclein are cultured in appropriate media under standard conditions (37°C, 5% CO2). (S)-Minzasolmin is dissolved in DMSO and diluted in culture medium to desired concentrations. Cells are treated with compound for specified durations. α-Synuclein oligomerization is assessed using oligomer-specific antibodies, immunofluorescence, or biochemical fractionation. Cell viability and cytotoxicity are assessed using MTT or LDH assays. Each concentration is tested in replicate wells with vehicle controls. Activity is compared to the R-enantiomer (Minzasolmin).
|
| Animal Protocol |
For in vivo animal studies of (S)-Minzasolmin, no specific protocols have been published in the available literature. For general in vivo administration of α-synuclein oligomerization inhibitors, compounds are typically formulated in suitable vehicles and administered via appropriate routes. Dosing regimens vary by study objective. In Parkinson's disease models, animals may be administered α-synuclein pre-formed fibrils (PFFs) or use transgenic models. The S-enantiomer may be compared to the R-enantiomer in comparative studies. All procedures must follow institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (S)-Minzasolmin are expected to be similar to those of Minzasolmin, though stereochemistry may affect ADME properties. The compound has a molecular weight of 425.59, formula C23H31N5OS, and CAS number 1802518-91-7. Storage: typically at -20°C for powder; in solvent at -80°C. Solubility: soluble in DMSO and other organic solvents. The compound is the S-enantiomer of Minzasolmin. Specific pharmacokinetic parameters are not extensively reported for the S-enantiomer. It is for research use only.
|
| Toxicity/Toxicokinetics |
According to available safety information, (S)-Minzasolmin is intended for research use only and not for human therapeutic applications. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment (gloves, lab coat, safety goggles). The compound should be handled in a well-ventilated area. Avoid dust formation and inhalation. In case of skin contact, wash with plenty of soap and water. In case of eye contact, rinse cautiously with water for several minutes. No clinical toxicity data are available.
|
| References | |
| Additional Infomation |
(S)-Minzasolmin ((S)-UCB0599; (S)-NPT200-11) is an isomer of Minzasolmin, an inhibitor of α-synuclein oligomerization. It has a molecular weight of 425.59 and formula C23H31N5OS. The compound is the S-enantiomer used as a research tool to study stereochemical requirements. It is for research use only with no clinical development or regulatory approvals reported.
|
| Molecular Formula |
C23H31N5OS
|
|---|---|
| Molecular Weight |
425.590143442154
|
| Exact Mass |
425.224
|
| CAS # |
1802518-91-7
|
| Related CAS # |
Minzasolmin;1802518-92-8;(Rac)-Minzasolmin;1802518-63-3
|
| PubChem CID |
118286089
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
30
|
| Complexity |
556
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCC[C@@H](CC1=CNC2=CC=CC=C21)NC(=O)C3=CN=C(S3)N4CCN(CC4)C
|
| InChi Key |
GDFWCSZNQVAQGR-SFHVURJKSA-N
|
| InChi Code |
InChI=1S/C23H31N5OS/c1-3-4-7-18(14-17-15-24-20-9-6-5-8-19(17)20)26-22(29)21-16-25-23(30-21)28-12-10-27(2)11-13-28/h5-6,8-9,15-16,18,24H,3-4,7,10-14H2,1-2H3,(H,26,29)/t18-/m0/s1
|
| Chemical Name |
N-[(2S)-1-(1H-indol-3-yl)hexan-2-yl]-2-(4-methylpiperazin-1-yl)-1,3-thiazole-5-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3497 mL | 11.7484 mL | 23.4968 mL | |
| 5 mM | 0.4699 mL | 2.3497 mL | 4.6994 mL | |
| 10 mM | 0.2350 mL | 1.1748 mL | 2.3497 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
